Literature DB >> 23846131

Plasma kallikrein: the bradykinin-producing enzyme.

J Björkqvist1, A Jämsä, T Renné.   

Abstract

Plasma prekallikrein is the liver-derived precursor of the trypsin-like serine protease plasma kallikrein (PK) and circulates in plasma bound to high molecular weight kininogen. The zymogen is converted to PK by activated factor XII. PK drives multiple proteolytic reaction cascades in the cardiovascular system such as the intrinsic pathway of coagulation, the kallikrein-kinin system, the fibrinolytic system, the renin-angiotensin system and the alternative complement pathway. Here, we review the biochemistry and cell biology of PK and focus on recent in vivo studies that have established important functions of the protease in procoagulant and proinflammatory disease states. Targeting PK offers novel strategies not previously appreciated to interfere with thrombosis and vascular inflammation in a broad variety of diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23846131     DOI: 10.1160/TH13-03-0258

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  48 in total

1.  A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.

Authors:  K-A Steen Burrell; J Layzer; B A Sullenger
Journal:  J Thromb Haemost       Date:  2017-08-02       Impact factor: 5.824

2.  2013 scientific sessions Sol Sherry distinguished lecture in thrombosis: polyphosphate: a novel modulator of hemostasis and thrombosis.

Authors:  Stephanie A Smith; James H Morrissey
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-23       Impact factor: 8.311

3.  Kinins in Glioblastoma Microenvironment.

Authors:  Mona N Oliveira; Barbara Breznik; Micheli M Pillat; Ricardo L Pereira; Henning Ulrich; Tamara T Lah
Journal:  Cancer Microenviron       Date:  2019-08-16

4.  Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.

Authors:  Zilun Hu; Pancras C Wong; Paul J Gilligan; Wei Han; Kumar B Pabbisetty; Jeffrey M Bozarth; Earl J Crain; Timothy Harper; Joseph M Luettgen; Joseph E Myers; Vidhyashankar Ramamurthy; Karen A Rossi; Steven Sheriff; Carol A Watson; Anzi Wei; Joanna J Zheng; Dietmar A Seiffert; Ruth R Wexler; Mimi L Quan
Journal:  ACS Med Chem Lett       Date:  2015-04-08       Impact factor: 4.345

5.  Hemodynamics and vasoactive substance levels during renal congestion that occurs in the anhepatic phase of liver transplantation.

Authors:  Zhong-Xin Li; Man-Cai Wang; You-Cheng Zhang; Jie Mao; Mo Chen; Rui Ni; Feng-Xian Wei; Gen-Nian Wang; Ling-Yi Zhang
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

Review 6.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

Review 7.  The initiation and effects of plasma contact activation: an overview.

Authors:  Lisha Lin; Mingyi Wu; Jinhua Zhao
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

Review 8.  Kallikrein-kinin in stem cell therapy.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

9.  Limited role of kininogen in the host response during gram-negative pneumonia-derived sepsis.

Authors:  Chao Ding; Cornelis van 't Veer; Joris J T H Roelofs; Meenal Shukla; Keith R McCrae; Alexey S Revenko; Jeff Crosby; Tom van der Poll
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-11-09       Impact factor: 5.464

10.  Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.

Authors:  H M H Spronk; T Padro; J E Siland; J H Prochaska; J Winters; A C van der Wal; J J Posthuma; G Lowe; E d'Alessandro; P Wenzel; D M Coenen; P H Reitsma; W Ruf; R H van Gorp; R R Koenen; T Vajen; N A Alshaikh; A S Wolberg; F L Macrae; N Asquith; J Heemskerk; A Heinzmann; M Moorlag; N Mackman; P van der Meijden; J C M Meijers; M Heestermans; T Renné; S Dólleman; W Chayouâ; R A S Ariëns; C C Baaten; M Nagy; A Kuliopulos; J J Posma; P Harrison; M J Vries; H J G M Crijns; E A M P Dudink; H R Buller; Y M C Henskens; A Själander; S Zwaveling; O Erküner; J W Eikelboom; A Gulpen; F E C M Peeters; J Douxfils; R H Olie; T Baglin; A Leader; U Schotten; B Scaf; H M M van Beusekom; L O Mosnier; L van der Vorm; P Declerck; M Visser; D W J Dippel; V J Strijbis; K Pertiwi; A J Ten Cate-Hoek; H Ten Cate
Journal:  Thromb Haemost       Date:  2018-01-29       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.